UPDATED: Clinician FAQS and guidance on COVID-19 vaccine

The Clinician FAQS and guidance on COVID-19 vaccine for patient receiving SACT. Version 6.0. Updated 21st December 2021 is now available on the UKCB website here: https://www.ukchemotherapyboard.org/publications. 

This updated guidance version 6 changes:
•    FAQ 1 Clarification for hormonal agents
•    FAQ 8 updated to reflect reinforcing (booster) dose after 3 primary doses.
•    FAQ13a: Updated figure
•    FAQ 13 FAQ 13b Updated to reflect change in recommendation about optimal timing.
•    New FAQ 14 added to reflect need for a reinforcing (booster) dose after 3rd primary dose

Please share with your colleagues.

Have a Merry Christmas and Happy New Year

Netty Cracknell and Pinkie Chambers
Co-chairs of the UK Chemotherapy Board

Latest News

By Clayton Wong on 13th October 2025

Join the Upcoming Pharmacists Webinar: Interactive Case Study on Prevention and Treatment of Fungal Infections in Stem Cell Transplant Patients

  On Thursday 23 October at 16:00 CEST, the EBMT Pharmacist Committee hosts a free webinar on on prevention and treatment of fungal infections in HCT patients. Save your seat…

Read article
By BOPA E&T Subcommittee on 10th October 2025

SAVE THE DATE: BOPA Introduction to Cancer Course, Scotland, March 2026

The popular Introduction to Cancer Course is coming to to Glasgow in March 2026 The BOPA Introduction to Cancer Course 2026 WHEN: Thursday 26th & Friday 27th March 2026 WHERE: The…

Read article
By ISOPP & BOPA on 8th October 2025

ISOPP & BOPA Joint Webinar: Sitting in the opposite chair, part of London Global Cancer Week – 2025

The upcoming ISOPP & BOPA joint webinar, Sitting in the opposite chair, part of London Global Cancer Week – 2025, will take place on November 26, 2025 at 7:00 PST…

Read article
By BOPA Executive Committee on 7th October 2025

BOPA 2025 Annual Report NOW Published

BOPA Annual Report 2025 – BOPA Welcome to the 2025 BOPA Annual Report. The last year has been another excellent year for BOPA. As you can see from our report…

Read article